Doctor's Data Inc

CardioMetabolic Profile; serum

This advanced test evaluates risk factors for cardiovascular disease (CVD) plus metabolic factors associated with metabolic syndrome and type II diabetes.  In addition to the traditional CVD risk factors, the test includes much more clinically sensitive atherogenic lipoprotein sub-species, the primary apolipoproteins, arterial inflammation and the activity of the lipoprotein- associated phospholipase- A2 (PLAC).  PLAC activity is a very sensitive indicator of active atherogenesis and instability of advanced arterial plaque.  Metabolic syndrome (MetS) is centered around insulin resistance and atherogenic dyslipoproteinemia, and is a risk factor associated with CVD and kidney disease. The test includes cystatin C to better assess glomerular filtration, and 1,5-anhydroglucitol (Glycomark®) that is a better indicator of hyperglycemic episodes than HbA1C.  The primary adipokines associated with insulin sensitivity and hepatic fatty acid metabolism are also addressed.
Learn more »

Turnaround Time

5 to 7 days

Analytes Tested

Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.


Analyte CPT ABN Required
Adiponectin; serum 83520 Yes
Apolipoprotein, A1; serum 82172 Yes
Apolipoprotein, B, serum 82172 Yes
C-Reactive Protein; serum 86141 No
Cholesterol; serum 80061 Yes
Creatinine; serum with eGFR 82565 No
Cystatin C; serum 82610 No
Glucose; serum 82947 No
Glycomark (1,5-AG); serum 84378 Yes
HDL; serum * Yes
Homocysteine; serum 83090 No
Insulin; serum 83525 No
LDL; serum * Yes
Leptin : Adiponectin ratio No
Leptin; serum 83520 Yes
Lipoprotein (a), serum 83695 No
Oxidized LDL; serum 83520 No
PLAC (LP-PLA2 Activity); serum 83698 Yes
Triglycerides; serum * Yes
small dense LDL; serum 84999 Yes

List price applies when filing with insurance or Medicare, or when billing a patient directly.

Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.

Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.

The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.

Sign in at the top of any page to view pricing and order tests. Or click here to create an account. You may also contact us for assistance placing an order.

This test is useful for

  • Family or personal history of CVD
  • Excess abdominal fat
  • Obesity
  • Insulin resistance
  • Fatty liver disease

Detailed Information

Cardiovascular disease (CVD) remains the second leading cause of death in North America. Metabolic syndrome (MetS) is a risk factor for CVD and renal damage. Therefor this comprehensive test evaluates risk for CVD plus too often associated MetS. Many of the risk factors and metabolic abnormalities associated with both CVD and MetS are lifestyle related. Objective advanced laboratory assessment of abnormalities in glucose, lipid and lipoprotein metabolism and adipokines facilitate individualized clinical intervention and can improve clinical outcomes.
Cardiovascular Risk
Well beyond the traditional levels of serum total lipids and lipoprotein cholesterol levels, this test assesses the levels of the most highly atherogenic apolipoprotein B containing lipoproteins. Formulas can used to calculate the levels of low density (LDL) and very low density VLDL) lipoprotein cholesterol, but when plasma triglycerides (TG) are high the calculated LDL and VLDL cholesterol values may be markedly underestimated. Assessment of non-HDL lipoprotein cholesterol levels, irrespective of TG levels provides accurate assessment of cholesterol transported in atherogenic LDL sub-species, VLDL, IDL and remnant particles. The levels of the real LDL culprits such as oxidized LDL, small dense LDL and lipoprotein(a) have much greater predictive power than LDL-cholesterol. The levels of the important protein constituents of anti-atherogenic HDL (apo AI) and atherogenic LDL species (apo B) are also reported. CVD is an inflammatory condition so artery-specific hsCRP levels are reported. The enzymatic activity of lipoprotein-associated phospholipase-A2 (PLAC®) provides an indication of very significant atherogenic disease activity, inflammation and increased risk for rupture of advanced plaque. Elevated PLAC activity is a very strong predictor of coronary events and CVD-related mortality regardless of cholesterol levels.
Metabolomics
MetS with core features of insulin resistance, central adiposity and mixed dyslipidemia is associated with risk for CVD and kidney disease. Fasting glucose and insulin levels are augmented with a sensitive biomarker of hyperglycemic episodes that are missed using HbA1C. Low serum levels of the dietary glucose-like sugar 1,5-anhydroglucitol (1,5-AG, Glycomark®) indicate daily hyperglycemic episodes over the past two weeks. Postprandial hyperglycemia is associated with cardiovascular disease and renal damage, and reduction of hyperglycemic events appears to decrease macro- and microvascular complications in diabetic patients. Cystain C is an excellent maker of glomerular filtration. As glomerular function declines, the serum levels of cystatin C rise. Cystatin C is an extracellular cysteine protease inhibitor that is produced by almost all cells. As such it is considered to be a better indicator of GFR than serum creatinine or calculated estimated GFR (eGFR).
Adipokines, hormones produced by fat cells, are regulators of insulin sensitivity, inflammation, oxidative stress and hepatic fatty acid oxidation and secretion of plasma triglycerides. With increased adiposity the level of adiponectin declines. Low levels of adiponectin are associated with marked increases in risk for developing metabolic syndrome, type II diabetes and coronary artery disease. In contrast levels of leptin increase due to leptin resistance that is associated with loss of appetite regulation (satiety). A high of leptin to adiponectin ratio (LAR) is associated with diminished anti-inflammatory, anti-atherogenic, anti-diabetic, anti-oxidative properties, and endothelial dysfunction. There is increased concern with respect to CVD when a high LAR is concomitant with elevated hsCRP (3-10 mg/L).

Cardiometabolic

Find out more